Catalog and comparison of societal preferences (Utilities) for lung cancer health states: Results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study

Medical Decision Making

Volumn 35, Issue 3, 2015, Pages 371-387

  Tramontano, Angela C ^a   Schrag, Deborah L ^b,d   Malin, Jennifer K ^c   Miller, Melecia C ^a   Weeks, Jane C ^b   Swan, J Shannon ^a,d   McMahon, Pamela M ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

EQ5D; lung cancer; quality of life; SF6D; utilities

Indexed keywords

AGE; AGED; ANCESTRY GROUP; CANCER STAGING; COMORBIDITY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH STATUS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGY; PSYCHOMETRY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; CONTINENTAL POPULATION GROUPS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84924980925     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X15570364     Document Type: Article

References (37)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC Cost-Effectiveness in Health and Medicine. New York: Oxford University Press ; 1996 :
2. Ware JE, Kosinski M, Bjorner JB, et al User's Manual for the SF-36v2 Health Survey. Lincoln (RI): Quality Metric, Inc. ; 2007 :
3. Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000 ; 18: 3302-17
4. Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010 ; 30 (6). 685-93
5. Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics. 2005 ; 23: 1143-53
6. Ayanian JZ, Chrischilles EA, Fletcher RH, et al. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004 ; 22: 2992-6
7. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990 ; 16: 199-208
8. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005 ; 43: 203-20
9. Malin JL, Ko C, Ayanian JZ, et al. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer. 2006 ; 14: 837-48
10. Calculating the U.S. Population-Based EQ-5D Index Score. Rockville (MD): AHRQ ; 2005 :
11. Shaw JW, Johnson JA, Chen S, Levin JR, Coons SJ. Racial/ethnic differences in preferences for the EQ-5D health states: results from the U.S. valuation study. J Clin Epidemiol. 2007 ; 60: 479-90
12. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004 ; 42: 851-9
13. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994 ; 30A: 635-42
14. Hinz A, Einenkel J, Briest S, Stolzenburg JU, Papsdorf K, Singer S. Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30?. Eur J Cancer Care. 2012 ; 21: 677-83
15. Hart A. Mann-Whitney test is not just a test of medians: differences in spread can be important. BMJ. 2001 ; 323: 391-3
16. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010 ; 363: 1495-7
17. Luo N, Johnson JA, Shaw JW, Coons SJ. Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Med Care. 2009 ; 47: 53-60
18. Palta M, Chen HY, Kaplan RM, Feeny D, Cherepanov D, Fryback DG. Standard error of measurement of 5 health utility indexes across the range of health for use in estimating reliability and responsiveness. Med Decis Making. 2011 ; 31: 260-9
19. Fryback DG, Palta M, Cherepanov D, Bolt D, Kim JS. Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Med Decis Making. 2010 ; 30: 5-15
20. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007 ; 45: 1162-70
21. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 ; 20: 1727-36
22. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012 ; 15: 708-15
23. Grutters JP, Joore MA, Wiegman EM, et al. Health-related quality of life in patients surviving non-small cell lung cancer. Thorax. 2010 ; 65: 903-7
24. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res. 1995 ; 4: 293-307
25. Bottomley A, Gaafar R, Manegold C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006 ; 24: 1435-42
26. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer. 1994 ; 73: 2087-98
27. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007 ; 5: 70
28. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003 ; 1: 4
29. Cherepanov D, Palta M, Fryback DG. Underlying dimensions of the five health-related quality-of-life measures used in utility assessment: evidence from the National Health Measurement Study. Med Care. 2010 ; 48: 718-25
30. Chen E, Nguyen J, Cramarossa G, et al. Symptom clusters in patients with lung cancer: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2011 ; 11: 433-9
31. Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014 ; 22: 181-7
32. Chen L, Antras L, Duh MS, et al. Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer. Curr Med Res Opin. 2007 ; 23: 2741-52
33. Brazier JE, Rowen D, Mavranezouli I, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess. 2012 ; 16: 1-114
34. Johnson JA, Luo N, Shaw JW, Kind P, Coons SJ. Valuations of EQ-5D health states: are the United States and United Kingdom different?. Med Care. 2005 ; 43: 221-8
35. Tomlinson G, Bremner KE, Ritvo P, Naglie G, Krahn MD. Development and validation of a utility weighting function for the patient-oriented prostate utility scale (PORPUS). Med Decis Making. 2012 ; 32: 11-30
36. Sundaram M, Smith MJ, Revicki DA, Miller LA, Madhavan S, Hobbs G. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index. Pharmacoeconomics. 2010 ; 28: 201-16
37. Pickard AS, Ray S, Ganguli A, Cella D. Comparison of FACT- and EQ-5D-based utility scores in cancer. Value Health. 2012 ; 15: 305-11